Search
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking
Quinine
go.drugbank.com/drugs/DB00468ApprovedInvestigationalQuinine (GLS-1200) was also investigated in clinical trials for its efficacy in preventing SARS-CoV-2 infection (NCT04408183, terminated) and is planned to be evaluated for preventing sinusitis after endoscopic … It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis.
Pitavastatin
go.drugbank.com/drugs/DB08860ApprovedInvestigational[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD … as well as the need for surgical revascularization or angioplasty following a heart attack.
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaForeskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedIt is used for grafting onto partial-thickness wounds, where it offers a favorable matrix for host cell migration [L2452]. … Foreskin keratinocytes are a form of skin cells that are cultured as a skin cell replacement for wounds, to accelerate wound closure and healing [L2434], [L2460].
Human papillomavirus type 11 L1 capsid protein antigen
go.drugbank.com/drugs/DB10300ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION, GARDASIL SUSPENSION FOR INJECTIONDelgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan, delgocitinib was also approved by the European Commission on September 23, 2024. It works to reduce the inflammatory response in inflammatory s...
Categories: Agents for Dermatitis, Excluding CorticosteroidsAcipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid....
Quinacrine
go.drugbank.com/drugs/DB01103InvestigationalAn acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.
Tick-borne encephalitis vaccine (whole virus, inactivated)
go.drugbank.com/drugs/DB16611ApprovedInvestigational[A237505, A237520] While some patients recover fully following neurological TBE, neurological sequelae can last for years and rare chronic forms of the disease have also been noted. … [A237520] TICOVAC (also known as TicoVac or FSME-IMMUN) was the first approved vaccine against TBE in Europe, first approved in 1976.
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A221456] There are four JAK subtypes which include JAK1, JAK2, JAK3, and tyrosine kinase 2.